Kura Oncology (KURA) Debt to Equity (2023 - 2025)
Kura Oncology (KURA) has disclosed Debt to Equity for 3 consecutive years, with $0.06 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 142.23% to $0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.06 through Dec 2025, up 142.23% year-over-year, with the annual reading at $0.06 for FY2025, 142.23% up from the prior year.
- Debt to Equity for Q4 2025 was $0.06 at Kura Oncology, up from $0.04 in the prior quarter.
- The five-year high for Debt to Equity was $0.06 in Q4 2025, with the low at $0.02 in Q1 2024.
- Average Debt to Equity over 3 years is $0.03, with a median of $0.02 recorded in 2023.
- The sharpest move saw Debt to Equity fell 20.26% in 2024, then skyrocketed 142.23% in 2025.
- Over 3 years, Debt to Equity stood at $0.02 in 2023, then fell by 1.99% to $0.02 in 2024, then surged by 142.23% to $0.06 in 2025.
- According to Business Quant data, Debt to Equity over the past three periods came in at $0.06, $0.04, and $0.03 for Q4 2025, Q3 2025, and Q2 2025 respectively.